Condition: Depressive Symptoms · Depression · Alzheimer Disease · Sponsor: Johns Hopkins University
This open-label pilot study examines whether the hallucinogenic drug, psilocybin, given under supportive conditions, is safe and effective for depression in people with Mild Cognitive Impairment (MCI) or early Alzheimer's Disease (AD). This study will also assess whether psilocybin may improve quality of life in those individuals.
This description comes directly from the study's public registry record.
Ian Geithner, MPS · 4105505466 · igeithn1@jhmi.edu
Albert Garcia-Romeu, PhD · 4105501972 · agarci33@jhmi.edu
Always discuss trial participation with your own doctor first.
| Johns Hopkins Center for Psychedelic and Consciousness Research | Baltimore, Maryland, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04123314